NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. CALGARY, Alberta, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Alaris Royalty Corp. ("Alaris" or the "Corporation") (TSX:AD) is pleased to announce that Agility Health Holdings, Inc. (“AHI”), the parent company of Agility Health LLC (“Agility LLC”), and Alaris have entered into a definitive agreement (the “Purchase Agreement”) with a third party buyer (the “Buyer”) pursuant to which AHI will sell 100% of its interest in Agility LLC (the “Agility Sale”), resulting in Alaris receiving gross proceeds of US$26.67 million (the “Gross Proceeds”). Alaris expects that the Agility Sale will close by February 28, 2018. However, the Agility Sale is subject to customary closing conditions and regulatory approvals, including approval by AHI’s shareholders and the TSX Venture Exchange. Alaris will provide an update on the expected closing when available. The Gross Proceeds to Alaris from the Agility Sale consist of: (i) US$22.23 million for the preferred units (the “Repurchase Price”) Alaris holds in Agility LLC (the “Agility Units”), which includes a premium of US$2.13 million over Alaris’ original cost of US$20.10 million (currently held at a fair value of $20.00 million); (ii) US$2.86 million for all unpaid distributions up to February 28, 2018; and (iii) US$1.58 million for a loan outstanding, including all principal and interest accrued on such loan. US$1.50 million of the Repurchase Price to be paid to Alaris will be placed in escrow for 18 months (the “Escrow Period”) to satisfy indemnification obligations under the Purchase Agreement. Following the Escrow Period any remaining escrowed funds will be paid to Alaris. Gross Proceeds to Alaris from this transaction will go towards debt reduction. Agility was advised by Livingstone Partners, LLC.